DDInter1956 DDInter1348
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity.
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Orlistat
Zalcitabine {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Hypokalaemia {u} (Side Effect) is caused by {v} (Compound) Orlistat
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Orlistat
Zalcitabine {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Hypokalaemia {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Zalcitabine {u} (Compound) causes {v} (Side Effect) Cough
Cough {u} (Side Effect) is caused by {v} (Compound) Telbivudine
Telbivudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Zalcitabine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Ergocalciferol
Ergocalciferol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Orlistat
Zalcitabine {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Ethanolamine Oleate
Ethanolamine Oleate {u} (Compound) resembles {v} (Compound) Orlistat
Zalcitabine {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Sodium Tetradecyl Sulfate
Sodium Tetradecyl Sulfate {u} (Compound) resembles {v} (Compound) Orlistat
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Orlistat
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Zalcitabine (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Orlistat (Compound)
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Orlistat (Compound)
Zalcitabine (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Zalcitabine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Telbivudine (Compound) and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Zalcitabine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Ergocalciferol (Compound) and Ergocalciferol may cause a minor interaction that can limit clinical effects when taken with Orlistat
Zalcitabine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Ethanolamine Oleate (Compound) and Ethanolamine Oleate (Compound) resembles Orlistat (Compound)
Zalcitabine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Sodium Tetradecyl Sulfate (Compound) and Sodium Tetradecyl Sulfate (Compound) resembles Orlistat (Compound)
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Orlistat (Compound)